Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Golimumab (Primary) ; Infliximab
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms PURSUIT 2
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 08 Oct 2018 Planned initiation date changed from 21 Sep 2018 to 11 Oct 2018.
    • 30 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top